Shattuck Labs, Inc. Contract Liability (Deferred Revenue)
Shattuck Labs, Inc. (STTK) had Contract Liability (Deferred Revenue) of $3.00 million as of 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-08-01
- 2024-06-30: Contract with Customer, Liability, Current $3.00M.
- 2024-03-31: Contract with Customer, Liability, Current $4.61M.
- 2023-12-31: Contract with Customer, Liability, Current $343.00K.
- 2023-09-30: Contract with Customer, Liability, Current $557.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2024-06-30 | $3.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $4.61M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $343.00K 10-Q · filed 2024-08-01 |
| 2023-09-30 | $557.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $743.00K 10-Q · filed 2023-08-10 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-09 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-15 |
| 2021-09-30 | $2.80M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $2.78M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $9.66M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $7.73M 10-K · filed 2022-03-15 |
| 2020-09-30 | $8.61M 10-Q · filed 2020-11-13 |
| 2019-12-31 | $12.89M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |